SCHEMBL6374648

SCHEMBL6374648

O/N=C(\c1ccc(O)cc1)c1ccc(O)cc1O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 14/20 0.68
ESR1 P03372 13/20 0.68
MGLL Q99685 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CES2 O00748 1/20 0.47
CA12 O43570 1/20 0.45
ALDH1A1 P00352 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
TSHR P16473 1/20 0.45
CA7 P43166 1/20 0.45
CA9 Q16790 1/20 0.45
CA14 Q9ULX7 1/20 0.45
HSP90AB1 P08238 1/20 0.44
MEN1 O00255 1/20 0.43
USP2 O75604 1/20 0.43
GAA P10253 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6374651 1.00 ESR2 (0.68) ESR2ESR1MGLLCYP1A2CYP3A4
SCHEMBL4746340 0.89 ESR2 (0.69) ESR2ESR1MGLLCYP1A2CYP3A4
SCHEMBL4746337 0.89 ESR2 (0.69) ESR2ESR1MGLLCYP1A2CYP3A4
SCHEMBL17988306 0.89 CYP1A2 (0.66) ESR2ESR1MGLLCYP1A2CYP3A4
SCHEMBL28348198 0.89 CYP1A2 (0.66) ESR2ESR1MGLLCYP1A2CYP3A4
SCHEMBL6374891 0.84 MGLL (0.65) ESR2ESR1MGLLCA12CA1
SCHEMBL6374895 0.84 MGLL (0.65) ESR2ESR1MGLLCA12CA1
SCHEMBL5072943 0.78 ESR2 (0.56) ESR2ESR1MGLLCYP3A4CA12
SCHEMBL11263514 0.73 ALDH1A1 (0.48) ESR2ESR1MGLLCYP1A2CYP3A4
SCHEMBL10661875 0.72 ESR1 (0.53) ESR2ESR1MGLLCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050159465-A1 3-(4-Hydroxy-2-methylphenyl)-1,2-benzisoxazol-6-ol; estrogen receptor modulators; ability to compete with 17 beta -estradiol for both Estrogen Receptor alpha and Estrogen Receptor beta; Estrogen Receptor Selective Agonist Antagonist activity; anticancer, antiinflammatory, anticholesterol WYETH (US) 2005-07-21 US disclosed
US-6884814-B2 Phenyl benzisoxazoles as estrogenic agents WYETH (US) 2005-04-26 US disclosed
US-20030207927-A1 Phenyl benzisoxazoles as estrogenic agents WYETH 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207927-A1 Phenyl benzisoxazoles as estrogenic agents ESR1, ESR2, GPER1 ESR2 2/4885ESR1 1/4885MGLL 4581/4885
US-20050159465-A1 3-(4-Hydroxy-2-methylphenyl)-1,2-benzisoxazol-6-ol; estrogen receptor modulators; ability to compete with 17 beta -estradiol for both Estrogen Receptor alpha and Estrogen Receptor beta; Estrogen Receptor Selective Agonist Antagonist activity; anticancer, antiinflammatory, anticholesterol ESR2, ESR1, GPER1 ESR2 1/4885ESR1 2/4885MGLL 2855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.